INDICATION & IMPORTANT SAFETY INFORMATION

Indication

FILSUVEZ is indicated for
the treatment of wounds
associated with dystrophic
and junctional epidermolysis
bullosa (EB) in adult and pediatric patients 6 months
of age and older.

Important Safety
Information

Warnings & Precautions

Local hypersensitivity and
skin reactions have been
reported in patients treated
with FILSUVEZ, including
urticaria and dermatitis.
If signs or symptoms of
hypersensitivity occur,
discontinue use immediately
and initiate appropriate
therapy.

Adverse Reactions

The most commonly reported adverse reaction
in clinical trials was pruritus
and pain at the wound
application site (7.3%).

Patient Counseling
Information

Please refer to Prescribing
Information for
administration instructions.

To report SUSPECTED
ADVERSE REACTIONS,
contact Chiesi USA Inc. at
1-888-661-9260 or FDA at
1-800-FDA-1088 or
www.fda.gov/medwatch.

Please see full Prescribing
Information.

©2025 Chiesi USA, Inc.
All rights reserved.
FILSUVEZ is a registered
trademark owned by the
Chiesi Group.
PP-RA-01219 V1.0